Plumbing the Core and Nibbling at the Margins of Cancer
Cancer Commons Editor in Chief George Lundberg, MD, is the face and curator of this invitation-only column
-
July 30, 2018
Forget Moonshots: Biomedicine Needs an Air Traffic Control System
With: Jeff Shrager, PhDA Q&A with Jeff Shrager, PhD, Director of Research, Cancer Commons; Adjunct Professor, Symbolic Systems Program, Stanford University Originally published May 17, 2017 Q: There never seem to be enough patients matched to cancer clinical trials to quickly test new cancer treatments. Might there be a better way, using new communication technology? A: Among the few things that everyone can agree upon, one is… Read more »
-
July 16, 2018
Proposed FDA “Conditional Approval”- More Details
With: Marty Tenenbaum, PhDAl Musella, DPMA Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published May 10, 2017 Q: Your April 5, 2017 blog post that proposed a new “Conditional” category for FDA drug approval elicited a number of positive and negative responses. Please explain the proposal in more detail… Read more »
-
July 9, 2018
Conditional Approval: Right Solution for the Wrong Problem
With:A Q&A with Shannon Brownlee, MS, Senior Vice President of the Lown Institute, a think tank in Boston. She is also co-founder of the Right Care Alliance, a social movement for transforming health care. Originally published April 26, 2017 Q: Musella and Tenenbaum recently proposed a new way, called conditional approval, for the American FDA to move potentially useful drugs to a patient market.… Read more »
-
July 2, 2018
A Proposed New FDA Drug Approval Pathway: “Conditional”
With: Marty Tenenbaum, PhDAl Musella, DPMA Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published April 5, 2017 Q: The delay time from discovery/observation, through validation to approval and distribution/use of new cancer treatments remains excessive. With promising experimental treatments, advanced computer technology and biostatistics, creative alternatives… Read more »
-
June 25, 2018
How to Tell a Patient Their Cancer Has Spread
With:A Q&A with crisis communication expert Lisa Dinhofer, MA, CT Q. As a counselor and communicator, you are expert and experienced in managing serious situational difficulties up to and including coping with sudden unexpected death. How would you think it best to approach a person with cancer who is being told, “your cancer has spread”? A: I’ll answer this question by posing another—how did… Read more »
-
April 19, 2018
How I Survive Cancer
A Q&A with Erin Maloney: Intrepid explorer, Amateur photographer, Aspiring leader; Toronto, ON Email: erinLmaloney@gmail.com Originally published Nov. 1, 2017 Q: You have recently disclosed that you have had a diagnosis of cancer and described your experience in some detail on Medium. What does it mean to you to be a “Cancer Survivor”? A: Calling myself a survivor sometimes feels like an exaggeration. In 2016, I… Read more »